Search results
Zai Lab doses first subject in Phase II plaque psoriasis treatment trial
Clinical Trials Arena via Yahoo Finance· 22 hours ago"Zai Lab doses first subject in Phase II plaque psoriasis treatment trial" was originally created...
Home Phototherapy for Psoriasis: Optimizing Access
Medscape· 2 days agoSupporters of home phototherapy for patients with plaque and guttate psoriasis had plenty to cheer about at the annual meeting of the American Academy of...
Finding the Best Psoriasis Treatment: How I Got Psoriasis Relief
Verywell Health via Yahoo News· 3 days agoWith two kids under 2, I needed some relief. I had been through enough psoriasis treatment and had...
Nail Psoriasis
Health via Yahoo News· 7 days agoBiopsy: Your provider might collect a biopsy (small skin sample) from the nail bed and send it to a laboratory for evaluation. Nail Psoriasis Treatment...
J&J’s Tremfya meets endpoints in Phase III ulcerative colitis trial
Clinical Trials Arena via Yahoo Finance· 3 days agoJ&J’s Tremfya is expected to be the successor to the company’s IL-12/IL-23 inhibitor Stelara...
Teva and Alvotech Announce SIMLANDI® (adalimumab-ryvk) Injection Now Available in the U.S.
Morningstar· 3 days ago“We are proud to make SIMLANDI available in the U.S. to patients and providers,” said Thomas Rainey...
Ultravate side effects: What they are and how to manage them
Healthline· 4 days agoUltravate (halobetasol propionate) is a prescription drug that’s used to treat plaque psoriasis. Ultravate can cause side effects that range from mild to ...
AbbVie Presents New Data Supporting Leading Gastroenterology Portfolio at 2024 Digestive Disease...
The Parsons Sun· 7 days ago- AbbVie will present 15 abstracts, including three oral presentations, in Crohn's disease and ulcerative colitis reinforcing AbbVie's commitment to advancing the standards of care in inflammatory bowel diseases (IBD)
State board targets six prescription drugs to review for affordability for Marylanders
Maryland Matters via Yahoo News· 3 days agoThe board will seek public comments, additional information and data over the next 60 days to...
Mizuho Boosts Arcutis Biotherapeutics (NASDAQ:ARQT) Price Target to $18.00
ETF DAILY NEWS· 6 days agoArcutis Biotherapeutics (NASDAQ:ARQT – Free Report) had its price target lifted by Mizuho from $17.00 to $18.00 in a report issued on Wednesday, Benzinga reports. They currently have a buy rating ...